Protara Therapeutics is a clinical-stage biopharmaceutical company developing innovative cell and molecular therapies focused on oncology and rare diseases. The company's primary program, TARA-002, is an investigational cell therapy in development for non-muscle invasive bladder cancer and lymphatic malformations, while its secondary program involves an investigational phospholipid substrate replacement therapy for patients receiving parenteral support. Protara has no approved products and generates no product revenues; the company finances operations through equity offerings and expects to incur substantial development and clinical trial expenses for several years before any potential regulatory approval and commercialization, with success dependent on navigating the FDA approval process and achieving commercial viability in its target markets.